Meir M Glick

US Patent:

7425339, Sep 16, 2008

Filed:

Jun 14, 2002

Appl. No.:

10/479509

Inventors:

Bent Karsten Jakobsen - Oxfordshire, GB
Meir Glick - Stoughton MA, US

Assignee:

MediGene Limited - Oxfordshire

International Classification:

A61K 38/17
C07K 14/725

US Classification:

4242781, 514 2, 514885, 530350, 530868

Abstract:

The present invention provides modified CD8 molecules whose binding to MHC is enhanced compared to wild-type CD8, wherein Serof at least one CD8α chain thereof is mutated to another amino acid. It also provides nucleic acids encoding such molecules and methods of using such molecules and nucleic acids in immunosuppressive therapy, in particular as inhibitors of cytotoxic T cell responses.

US Patent:

7569664, Aug 4, 2009

Filed:

Oct 3, 2003

Appl. No.:

10/530035

Inventors:

Bent Karsten Jakobsen - Oxfordshire, GB
Meir Glick - Stoughton MA, US

Assignee:

Immunocore Limited - Oxon

International Classification:

C07K 14/00
C07K 17/00

US Classification:

530350, 436501

Abstract:

A single chain T cell receptor (scTCR) comprising an a segment constituted by a TCR α chain variable region sequence fused to the N terminus of a TCR α chain constant region extracellular sequence, a β segment constituted by a TCR β chain variable region fused to the N terminus of a TCR β chain constant region extracellular sequence, and a linker sequence linking the C terminus of the α segment to the N terminus of the β segment, or vice versa, the constant region extracellular sequences of the α and β segments being linked by a disulfide bond, the length of the linker sequence and the position of the disulfide bond being such that the variable region sequences of the α and β segments are mutually orientated substantially as in native αβ T cell receptors. Complexes of two or more such scTCRs, and use of the scTCRs in therapy and in various screening applications are also disclosed.

US Patent:

7763718, Jul 27, 2010

Filed:

Oct 29, 2007

Appl. No.:

11/926391

Inventors:

Bent Karsten Jakobsen - Abingdon, GB
Meir Glick - Morristown NJ, US

Assignee:

Immunocore Limited

International Classification:

C07H 21/04
C12P 21/06
C12N 1/20
C12N 15/00

US Classification:

536 235, 4353201, 4352523, 435 691

Abstract:

The present invention provides a soluble T cell receptor (sTCR), which comprises (i) all or part of a TCR α chain, except the transmembrane domain thereof, and (ii) all or part of a TCR β chain, except the transmembrane domain thereof. (i) and (ii) each comprise a functional variable domain and at least a part of the constant domain of the TCR chain, and are linked by a disulphide bond between constant domain residues which is not present in native TCR.

US Patent:

20050009025, Jan 13, 2005

Filed:

Aug 30, 2002

Appl. No.:

10/486924

Inventors:

Bent Jakobsen - Oxon, GB
Meir Glick - Stoughton MA, US

International Classification:

C12Q001/68
A61K038/17
C07K014/705

US Classification:

435006000, 435069100, 435320100, 435325000, 514012000, 530350000, 536023500

Abstract:

The present invention provides a soluble T cell receptor (sTCR), which comprises (i) all for part of a TCR α chain, except the transmembrane domain thereof, and (ii) all or part of a TCR β chain, except the transmembrane domain thereof. (i) and (ii) each comprise a functional variable domain and at least a part of the constant domain of the TCR chain, and are linked by a disulphide bond between constant domain residues which is not present in native TCR.

US Patent:

20050114035, May 26, 2005

Filed:

Jan 20, 2003

Appl. No.:

10/502583

Inventors:

Daniel Robinson - Towcester Northants, GB
William Richards - Oxford, GB
Meir Glick - East Hanover NJ, US

Assignee:

Isis Innovation Limited - Oxford

International Classification:

G06F019/00
G01N033/48
G01N033/50

US Classification:

702019000

Abstract:

A method for identifying a binding site for a ligand on a macromolecule and the configuration of the ligand when bound, said method comprising using a multiscale approach to represent the ligand as a plurality of models having different levels of detail.

US Patent:

20060135418, Jun 22, 2006

Filed:

Nov 25, 2003

Appl. No.:

10/535965

Inventors:

Bent Jakobsen - Abingdon, GB
Meir Glick - Stoughton MA, US

Assignee:

Avidex Ltd. - Abingdon

International Classification:

A61K 38/17
C07K 14/705

US Classification:

514012000, 530350000

Abstract:

A multivalent T cell receptor (TCR) complex comprising at least two TCRs, linked by a non-peptidic polymer chain or a peptidic linker sequence. Preferably the TCR complex comprises TCR heterodimers having a non-native disulfide bond between constant domain residues, said TCRs being linked via an optionally substituted, polyalkylene glycol linker. Therapeutic agents such as cytotoxic drugs may be attached to such complexes for targeted cell delivery. Such TCR complexes may be used in the diagnosis or treatment of cancer, infectious disease, or autoimmune disease.

US Patent:

20080125369, May 29, 2008

Filed:

Oct 29, 2007

Appl. No.:

11/926480

Inventors:

Bent Karsten Jakobsen - Abingdon, GB
Meir Glick - Morristown NJ, US

Assignee:

AVIDEX LIMITED - Abingdon

International Classification:

A61K 38/17
C07K 14/435

US Classification:

514 12, 530350

Abstract:

The present invention provides a soluble T cell receptor (sTCR), which comprises (i) all or part of a TCRα chain, except the transmembrane domain thereof, and (ii) all or part of a TCR β chain, except the transmembrane domain thereof. (i) and (ii) each comprise a functional variable domain and at least a part of the constant domain of the TCR chain, and are linked by a disulphide bond between constant domain residues which is not present in native TCR.